DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

Conditions

• Liver Cancer
• Liver Metastases

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE. This collaborative registry focuses on identifying associations between baseline clinical/imaging parameters, clinical outcomes, and safety for patients undergoing PVE/HVE.

Key Dates

First listed

Jul 21, 2026

Start date

Mar 16, 2021

Status verified

Jul 2026

Primary completion

Nov 30, 2027

Completion

Nov 30, 2032

Study Design

Enrollment

350 participants (estimated)

Arms

• Arm: PVE/HVE
  This registry collects data on patients who have undergone combined portal and hepatic vein embolisation prior to major liver surgery.

Primary Outcome Measure

Resectability three weeks after PVE/HVE and 5 years overall survival [ Time Frame: From enrolment until 5 year follow up ]

Central Contacts

• Fenna Van der Zijden, Dr.
  +316 40911632
  [email protected]

Locations (3)

Find similar trials in Chicago, IL

Related Studies

• Integrated Cancer Repository for Cancer Research
  Recruiting · University of Nebraska · Greenwood Village, Colorado
• Biobank for Cholestatic Liver Diseases.
  Recruiting · Mayo Clinic · Rochester, Minnesota
• Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
  PHASE2 · Recruiting · Allison O'Neill, MD · San Francisco, California
• National Liver Cancer Screening Trial
  PHASE4 · Recruiting · University of Texas Southwestern Medical Center · Los Angeles, California